Search Within

Archie Tse

Formats
  1. Meeting Abstract (18)
  2. Journal Article (16)
Groups
  1. Department of Medicine (17)
  2. Solid Tumor Oncology Division (17)
  3. Center for Pancreatic Cancer Research (13)
  4. Gastrointestinal Oncology Service (12)
  5. Biostatistics Service (10)
  6. Body Imaging Service (10)

More Groups

People
  1. Gary Schwartz (31)
  2. Manish Shah (13)
  3. David Kelsen (9)
  4. Richard Carvajal (9)
  5. Robert Lefkowitz (7)
  6. Eileen O'Reilly (6)

More People

Years
  1. 2010 (3)
  2. 2009 (8)
  3. 2008 (4)
  4. 2007 (5)
  5. 2006 (3)
  6. 2005 (4)

More Years

Publications
  1. Journal of Clinical Oncology (12)
  2. Cancer Research (6)
  3. Clinical Cancer Research (5)
  4. Cancer Chemotherapy and Pharmacology (2)
  5. Proceedings of the American Association for Cancer Research Annual Meeting (2)
  6. Annals of Oncology (1)

More Publications

Publishers
  1. American Association for Cancer Research (14)
  2. American Society of Clinical Oncology (12)
  3. Springer (2)
  4. Karger (1)
  5. Oxford University Press (1)
  6. Pergamon-Elsevier Science Ltd (1)

More Publishers

Results (34)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI #6447)
    Meeting Abstract

    Shah, M. A.; Ramanathan, R. K.; Ilson, D.; Randazzo, J.; Schwartz, G. K.; Tse, A.; D'adamo, D.; Levner, A.; Capanu, M.; Kelsen, D. P.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinorna
    Journal Article

    Shah, M. A.; Ramanathan, R. K.; Ilson, D. H.; Levnor, A.; D'adamo, D.; O'reilly, E.; Tse, A.; Trocola, R.; Schwartz, L.; Capanu, M.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Aurora kinases: New targets for cancer therapy
    Journal Article

    Carvajal, R. D.; Tse, A.; Schwartz, G. K.
    Clinical Cancer Research (2006)

    Fulltext@MSK | Save
  • The Hsp90 inhibitor, 17-Allylamino-17-Demethoxygeldanamycin (17AAG) abrogates the G(2)/M DNA damage checkpoint and induces apoptosis selectively in p53-defective colon cancer cells by down-regulating both Chk1 and Wee1
    Meeting Abstract

    Tse, A. N.; Sheikh, T. N.; Schwartz, G. K.
    Cancer Research (2005)

    Fulltext@MSK | Save
  • A novel Aurora B kinase inhibitor is a potent anticancer agent which induces polyploidy and multinucleation with abnormal chromosomal segregation independent of the p53 status of the cell
    Meeting Abstract

    Nair, J. S.; Tse, A.; Cheema, H.; Ambrosini, G.; Keen, N.; Schwartz, G. K.
    Cancer Research (2005)

    Fulltext@MSK | Save
  • Suberoy1Anilide hydroxamic acid (SAHA), a histone deacetylase (HDAC) inhibitor, induces an aberrant mitotic effect evident by an abnormal bi-polar spindle and abnormal chromosomal segregation, resulting in incomplete cytokinesis of HCT-116 colon cancer cells
    Meeting Abstract

    Cheema, H. S.; Tse, A. N.; Nair, J.; Coward, J.; Ambrosini, G.; Schwartz, G. K.
    Cancer Research (2005)

    Fulltext@MSK | Save
  • Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
    Journal Article

    Chung, K. Y.; Shia, J.; Kemeny, N. E.; Shah, M.; Schwartz, G. K.; Tse, A.; Hamilton, A.; Pan, D.; Schrag, D.; Schwartz, L.; more...
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • CHIR 124, a novel and potent inhibitor of chk1, potentiates the anti-tumor activity of topoisomerase I poisons in vitro and in vivo
    Meeting Abstract

    Tse, A. N.; Embry, M.; Aardalen, K.; Shao, Y.; Rendahl, K.; Menezes, D.; Hibner, B.; Gesner, T.; Schwartz, G.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • 17-allylamino-17-demethoxygeldanamycin (17-AAG) abrogates the G(2)/M cell cycle checkpoint by down-regulating chk1 and selectively sensitizes tumor cells with defective p53 to topoisomerase I poison
    Meeting Abstract

    Tse, A. N.; Solit, D.; Rosen, N.; Schwartz, G.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F)
    Meeting Abstract

    Shah, M. A.; Kortmansky, J.; Gonen, M.; Tse, A.; Lefkowitz, R.; Kelsen, D.; Colevas, D.; Winkelman, J.; Yi, S.; Schwartz, G.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save